Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
- 13 November 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 18 (2), 316-325
- https://doi.org/10.1038/sj.leu.2403205
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Differences in CD33 Intensity Between Various Myeloid NeoplasmsAmerican Journal of Clinical Pathology, 2002
- Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)Leukemia, 2002
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001
- Gemtuzumab ozogamicinDrugs, 2001
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Chemistry and biology of natural and designed enediynes.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties.The Journal of Experimental Medicine, 1989
- Calicheamicin γ 1 I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site SpecificallyScience, 1988
- A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cellsLeukemia Research, 1984